Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
AEON Biopharma (AEON)
NYSE MKT:AEON
AEON Biopharma (AEON) Stock Price & Analysis
60 Followers
AEON Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.92 - $17.17
Previous Close$2.25
Volume522.69K
Average Volume (3M)1.67M
Market Cap
$88.03M
Enterprise Value$91.55M
Total Cash (Recent Filing)$1.56M
Total Debt (Recent Filing)$5.09M
Price to Earnings (P/E)―
Beta0.41
Next Earnings
Mar 29, 2024EPS Estimate
-$0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.14
Shares Outstanding39,122,238
10 Day Avg. Volume45,456
30 Day Avg. Volume1,672,141
Standard Deviation0.20
R-Squared0.01
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)-0.21
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda8.61
Forecast
1Y Price Target
$6.00Price Target Upside166.67% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
AEON Biopharma News
PremiumMarket News
3 Penny Stocks to Watch Now, 7/18/24
PremiumCompany Announcements
AEON Biopharma Halts Migraine Study and Evaluates Strategy
Bulls Say, Bears Say
Bulls Say
Clinical ProgressABP-450 is ready to enter Phase 3 in cervical dystonia (CD), which is viewed as a 'low-risk' program since it is one in which neuromodulators have performed very consistently in clinical studies over the years.
Market ExpansionA biosimilar pathway potentially provides ABP-450 with a fast and low-cost approach to launch in multiple indications.
Regulatory ApprovalThe FDA has proven increasingly comfortable to grant fully extrapolated labels to biosimilars, even in instances where there was some ambiguity in terms of the mechanism of action.
Bears Say
Clinical TrialsABP-450 did not show superiority in the preventive treatment of chronic migraine due to a high placebo effect.
CompetitionAeon is competing against entrenched players, most notably Abbvie, with greater resources.
FundingAeon must now navigate its path forward with limited capital.
---
Ownership Overview
40.70% Insiders
2.37% Mutual Funds
2.04% Other Institutional Investors
54.89% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
AEON FAQ
What was AEON Biopharma’s price range in the past 12 months?
AEON Biopharma lowest stock price was $0.92 and its highest was $17.17 in the past 12 months.
What is AEON Biopharma’s market cap?
Currently, no data Available
When is AEON Biopharma’s upcoming earnings report date?
AEON Biopharma’s upcoming earnings report date is Mar 29, 2024 which is 114 days ago.
How were AEON Biopharma’s earnings last quarter?
AEON Biopharma released its earnings results on Nov 13, 2023. The company reported $1.19 earnings per share for the quarter, beating the consensus estimate of -$0.53 by $1.72.
Is AEON Biopharma overvalued?
According to Wall Street analysts AEON Biopharma’s price is currently Undervalued.
Does AEON Biopharma pay dividends?
AEON Biopharma does not currently pay dividends.
What is AEON Biopharma’s EPS estimate?
AEON Biopharma’s EPS estimate is -$0.4.
How many shares outstanding does AEON Biopharma have?
AEON Biopharma has 39,122,240 shares outstanding.
What happened to AEON Biopharma’s price movement after its last earnings report?
AEON Biopharma reported an EPS of $1.19 in its last earnings report, beating expectations of -$0.53. Following the earnings report the stock price went down -1.196%.
Which hedge fund is a major shareholder of AEON Biopharma?
Among the largest hedge funds holding AEON Biopharma’s share is Saba Capital Management. It holds AEON Biopharma’s shares valued at N/A.
---
AEON Biopharma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.00 (166.67% Upside)
$6.00 (166.67% Upside)
Hedge Fund Trend
Decreased
By 636.2K Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-73.40%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-85.97%
Trailing 12-Months
Company Description
AEON Biopharma
Priveterra Acquisition Corp is a blank check company. It is formed for the purpose of effecting a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or other similar business combination with one or more businesses.
---
AEON Stock 12 Month Forecast
Average Price Target
$6.00
▲(166.67% Upside)
Technical Analysis
Best Analysts Covering AEON
1 Year
1 Year Success Rate
2/5 ratings generated profit
1 Year Average Return
-3.86%
reiterated a buy rating 12 days ago
Copying Douglas Tsao's trades and holding each position for 1 Year would result in 40.00% of your transactions generating a profit, with an average return of -3.86% per trade.
---